Firebrick Pharma (ASX:FRE) FCF Yield % : -41.35 (As of Jun. 23, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Firebrick Pharma's Trailing 12-Month Free Cash Flow is A$-4.60 Mil, and Market Cap is A$11.13 Mil. Therefore, Firebrick Pharma's FCF Yield % for today is -41.35%.

The historical rank and industry rank for Firebrick Pharma's FCF Yield % or its related term are showing as below:

ASX:FRE' s FCF Yield % Range Over the Past 10 Years
Min: -88.71 Med: 0 Max: 0
Current: -41.35

ASX:FRE's FCF Yield % is ranked worse than
89.44% of 1080 companies
in the Drug Manufacturers industry
Industry Median: -0.16 vs ASX:FRE: -41.35

Firebrick Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -55.84%.

Firebrick Pharma FCF Yield % Historical Data

The historical data trend for Firebrick Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma FCF Yield % Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

FCF Yield %

-9.47

-21.18

Firebrick Pharma Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
FCF Yield %	-	-11.29	-26.28	-22.78

Competitive Comparison of Firebrick Pharma's FCF Yield %

For the Drug Manufacturers - General subindustry, Firebrick Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firebrick Pharma's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's FCF Yield % falls into.

Firebrick Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Firebrick Pharma's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-5.785	/	27.318285
	=	-21.18%

Firebrick Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.014	*	2	/	8.90235
	=	-22.78%

Firebrick Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Firebrick Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma (ASX:FRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines